Oops, They Did It Again: Indian Pharma’s Frequent Flyers on FDA's Naughty List
18 July 2024 | Reports/white papers | By Sakshi Kamble | sakshi.kamble@biospectrumasia.com
The U.S. Food and Drug Administration (FDA) is a federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, food, cosmetics, and radiation-emitting products.
BioSpectrum India Graphics
One of the FDA's key regulatory actions includes issuing warning letters to pharmaceutical companies that fail to comply with current good manufacturing practice (CGMP) regulations.
These letters alert companies to significant violations and demand corrective actions to prevent potential health risks to consumers.
Indian pharmaceutical companies, which play a major role in the global drug supply chain, have been recipients of such FDA warning letters. The Indian pharmaceutical sector has witnessed many warnings issued by the FDA in 2023-2024. These letters typically address issues related to quality control, data integrity, manufacturing processes, and compliance with CGMP standards. Indian firms, including prominent manufacturers, often face scrutiny due to the scale of their operations and their critical role in supplying affordable generic medications worldwide.
The FDA's oversight ensures that these companies maintain high standards to protect patient health and safety, and non-compliance can result in significant consequences, including product recalls, import bans, and delays in drug approvals.
Recent FDA Warning Letters
Natco Pharma
Date: April 8, 2024
The FDA conducted an inspection of Natco Pharma Limited's drug manufacturing facility in Kothur Village Rangareddy, Telangana, India, from October 9 to 18, 2023. The inspection revealed significant violations of CGMP regulations for finished pharmaceuticals. These violations included inadequate cleaning, maintenance, and sanitation of equipment, leading to contamination risks. The response from Natco Pharma was deemed insufficient, and the FDA required a comprehensive assessment and corrective action plan. Natco Pharma has committed to temporarily suspend production of all drugs intended for the U.S. market while addressing the CGMP violations.
Insight: Natco Pharma's situation underscores the critical importance of robust cleaning protocols and comprehensive responses to regulatory findings. Temporary suspension of production can significantly impact revenue and market presence, emphasizing the need for proactive quality assurance measures.
Sun Pharmaceuticals
Date: June 18, 2024
An inspection of Sun Pharmaceutical Industries Limited, located in Dadra and Nagar Haveli, revealed significant CGMP violations. These included inadequate cleaning and maintenance of equipment, leading to contamination risks. The FDA noted repeated violations at multiple sites within Sun Pharmaceutical's network, indicating inadequate management oversight. The company was given 15 working days to respond with corrective actions and plans to prevent recurrence.
Insight: Sun Pharmaceuticals' recurring issues across multiple sites highlight systemic challenges within the company's quality management system. Addressing these requires not only localized fixes but also a top-down reevaluation of corporate governance and quality culture.
Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd.
Date: April 18, 2024
The FDA issued a warning letter to Dr. Sankunni’s Ayurvedic Research Foundation regarding serious violations related to the drug listing information submitted for multiple products. These discrepancies rendered the products misbranded, and the FDA emphasized the importance of accurate listing for patient safety. Immediate corrective actions were required, with a detailed response expected within 15 working days.
Insight: The case of Dr. Sankunni’s Ayurvedic Research Foundation highlights the critical role of accurate documentation and transparent communication with regulatory bodies. Misbranding not only jeopardizes patient safety but also erodes trust and market credibility.
Kilitch Healthcare India Limited
Date: March 28, 2024
Kilitch Healthcare's facility in Navi Mumbai was found to be operating under insanitary conditions, leading to adulteration of drug products. Violations included inadequate facility maintenance, poor aseptic practices, and deficiencies in the quality control unit's oversight and data integrity. The FDA demanded comprehensive remedial actions and a detailed plan for data integrity remediation.
Insight: Kilitch Healthcare’s violations emphasize the need for stringent aseptic practices and robust data integrity protocols. Ensuring a clean and controlled manufacturing environment is fundamental to maintaining product quality and patient safety.
Madhu Instruments Private Limited
Date: February 1, 2024
An FDA inspection of Madhu Instruments Private Limited revealed significant deficiencies in the manufacturing environment and equipment maintenance. The response to the FDA's Form 483 was deemed inadequate, and the FDA emphasized the necessity for robust corrective measures. The facility was placed on Import Alert 66-40, meaning products may be detained or refused admission into the United States unless compliance is confirmed.
Insight: Madhu Instruments’ situation illustrates the severe consequences of failing to maintain sanitary conditions and appropriate maintenance protocols. Import alerts can severely disrupt business operations and market access, necessitating immediate and effective corrective actions.
Patcos Cosmetics Pvt. Ltd.
Date: December 15, 2023
Patcos Cosmetics Pvt. Ltd. faced significant CGMP violations, including failure to conduct proper identity tests for high-risk components susceptible to contamination. The FDA placed the firm on Import Alert 66-40 and required prompt corrective actions and a detailed response within 30 working days.
Insight: Patcos Cosmetics' failure to conduct identity tests for high-risk components underscores the critical need for thorough quality control testing. Ensuring the safety of ingredients is paramount to prevent harmful contamination and maintain consumer trust.
Intas Pharmaceuticals Limited
Date: November 21, 2024
An inspection of Intas Pharmaceuticals Limited's facility in Ahmedabad revealed significant CGMP violations, including data integrity issues and failures in investigating discrepancies. The FDA demanded detailed remediation plans and effective executive management oversight.
Insight: Intas Pharmaceuticals’ data integrity issues highlight the essential role of accurate and reliable record-keeping in pharmaceutical manufacturing. Addressing these issues requires a comprehensive overhaul of data management systems and enhanced oversight from executive leadership.
Cipla Limited
Date: November 17, 2024
Cipla Limited’s facility in Indore faced significant CGMP violations, including inadequate investigations into quality defect complaints and media fill contamination incidents. The FDA requested comprehensive corrective actions and independent assessments of their investigation system and CAPA program.
Insight: Cipla Limited's case underscores the importance of thorough investigation and resolution of quality complaints. Effective CAPA programs are vital to prevent recurring issues and ensure continuous improvement in manufacturing practices.
Global Pharma HealthCare Private Limited
Date: October 20, 2023
Global Pharma Healthcare faced significant CGMP violations, including failure to conduct Antimicrobial Effectiveness Testing and inadequate cleanroom practices. The FDA requested a comprehensive risk assessment and remediation plan addressing all contamination hazards.
Insight: The failure to conduct critical testing, such as Antimicrobial Effectiveness Testing, at Global Pharma Healthcare highlights the risks associated with inadequate product safety evaluations. Implementing rigorous testing protocols is essential to safeguard public health.
Sun Pharmaceutical Industries Ltd. (Halol Facility)
Date: October 16, 2023
An inspection of Sun Pharmaceutical’s Halol facility revealed significant CGMP violations, including inadequate aseptic practices and cleanroom design. The FDA required a comprehensive action plan and the engagement of a CGMP consultant.
Insight: Sun Pharmaceutical’s Halol facility underscores the complexity of maintaining aseptic conditions in drug manufacturing. Comprehensive action plans and external consulting can provide valuable expertise to address systemic issues.
Jubilant Generics Limited
Date: March 6, 2019
The FDA inspection of Jubilant Generics Limited’s facility revealed significant CGMP violations, including inadequate investigation of batch failures and insufficient quality control. The FDA recommended hiring a qualified CGMP consultant to ensure compliance.
Insight: Jubilant Generics' recurring CGMP violations highlight the need for sustained improvements in quality management systems. Engaging external consultants can provide the necessary expertise to achieve compliance and enhance operational standards.
Medgel Private Limited
Date: July 20, 2023
Medgel Private Limited faced significant CGMP violations, including inadequate investigation of batch failures and poor data integrity practices. The FDA requested a detailed plan to address these deficiencies and improve CGMP systems.
Insight: Medgel's violations demonstrate the critical importance of thorough batch failure investigations and maintaining data integrity. Addressing these issues is fundamental to ensuring product quality and regulatory compliance.
Centaur Pharmaceuticals Private Ltd. (Pune Facility)
Date: July 25, 2023
An inspection of Centaur Pharmaceuticals’ Pune facility revealed significant CGMP violations, including inadequate cleaning procedures and insufficient quality control. The FDA required a comprehensive remediation plan and independent evaluation of cleaning effectiveness.
Insight: Centaur Pharmaceuticals’ Pune facility highlights the necessity of maintaining rigorous cleaning procedures and quality control measures. Independent evaluations can provide objective assessments to identify and rectify deficiencies.
Centaur Pharmaceuticals Private Ltd. (Ambernath Facility)
Date: June 5, 2024
Centaur Pharmaceuticals’ Ambernath facility faced significant deviations from CGMP for active pharmaceutical ingredients, including inadequate document control and cleaning practices. The FDA requested a detailed corrective action and preventive action plan.
Insight: Centaur Pharmaceuticals’ Ambernath facility underscores the critical role of document control and cleaning practices in ensuring compliance with CGMP. Detailed CAPA plans are essential to address root causes and prevent recurrence of violations.
Cleaning Up Their Act: Indian Pharma’s Brush with FDA Reality Check – Will They Finally Learn?
